Ola Landgren mainly focuses on Internal medicine, Multiple myeloma, Immunology, Monoclonal gammopathy of undetermined significance and Oncology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. His Multiple myeloma research is multidisciplinary, incorporating elements of Incidence, Disease, Pathology, Hazard ratio and Transplantation.
His studies in Immunology integrate themes in fields like Odds ratio, First-degree relatives and Case-control study. Ola Landgren interconnects Genetic predisposition, Immunofixation, Asymptomatic, Prospective cohort study and Veterans Affairs in the investigation of issues within Monoclonal gammopathy of undetermined significance. He works mostly in the field of Oncology, limiting it down to topics relating to Hematology and, in certain cases, Risk profile, Monoclonal gammopathy, Treatment strategy, Dyscrasia and Unknown Significance, as a part of the same area of interest.
His primary areas of study are Internal medicine, Multiple myeloma, Oncology, Immunology and Monoclonal gammopathy of undetermined significance. His Internal medicine research incorporates elements of Gastroenterology and Surgery. His studies deal with areas such as Pathology, Disease, Bone marrow and Minimal residual disease as well as Multiple myeloma.
His Oncology research integrates issues from Clinical trial, Transplantation, Melphalan, Daratumumab and Leukemia. Ola Landgren has researched Immunology in several fields, including Odds ratio and Case-control study. His study looks at the relationship between Monoclonal gammopathy of undetermined significance and topics such as Hazard ratio, which overlap with Proportional hazards model.
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Monoclonal gammopathy of undetermined significance. The concepts of his Multiple myeloma study are interwoven with issues in Cancer research, Computational biology and Bone marrow, Minimal residual disease. Ola Landgren conducts interdisciplinary study in the fields of Internal medicine and In patient through his works.
His Oncology study combines topics from a wide range of disciplines, such as Odds ratio, Melphalan, Newly diagnosed, Refractory Multiple Myeloma and Surrogate endpoint. His research integrates issues of Maintenance therapy and Cohort in his study of Lenalidomide. His Monoclonal gammopathy of undetermined significance research includes elements of Peripheral neuropathy, Cancer, Prospective cohort study and Risk factor.
His main research concerns Multiple myeloma, Internal medicine, Oncology, Minimal residual disease and Lenalidomide. His research in Multiple myeloma intersects with topics in Monoclonal gammopathy of undetermined significance, Cancer, Disease and Bone marrow. All of his Internal medicine and Phases of clinical research, Clinical trial, Daratumumab, Cohort study and Odds ratio investigations are sub-components of the entire Internal medicine study.
His Progression-free survival study, which is part of a larger body of work in Oncology, is frequently linked to Risk assessment, bridging the gap between disciplines. His biological study spans a wide range of topics, including Plasma Cell Myeloma, Clone, Drug approval and Somatic evolution in cancer. His Lenalidomide research incorporates elements of Clinical endpoint, Tolerability and Propensity score matching.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study
Ola Landgren;Robert A. Kyle;Ruth M. Pfeiffer;Jerry A. Katzmann.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
Solid cancers after allogeneic hematopoietic cell transplantation
J. Douglas Rizzo;Rochelle E. Curtis;Gérard Socié;Kathleen A. Sobocinski.
B-cell clones as early markers for chronic lymphocytic leukemia.
Ola Landgren;Maher Albitar;Wanlong Ma;Fatima Abbasi.
The New England Journal of Medicine (2009)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren;Ethel S. Gilbert;J. Douglas Rizzo;Gérard Socié.
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus
Thomas P. Giordano;Louise Henderson;Louise Henderson;Ola Landgren;Elizabeth Y. Chiao;Elizabeth Y. Chiao.
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
Ola Landgren;Gloria Gridley;Ingemar Turesson;Neil E. Caporaso.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: